ABBADESSA, GIULIA
ABBADESSA, GIULIA
DIPARTIMENTO DI STUDI UMANISTICI
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors
2023 Petracca, M; Carotenuto, A; Scandurra, C; Moccia, M; Rosa, L; Arena, S; Ianniello, A; Nozzolillo, A; Turrini, M; Streito, L M; Abbadessa, G; Cellerino, M; Bucello, S; Ferraro, E; Mattioli, M; Chiodi, A; Inglese, M; Bonavita, S; Clerico, M; Cordioli, C; Moiola, L; Patti, F; Lavorgna, L; Filippi, M; Borriello, G; D'Amico, E; Pozzilli, C; Brescia Morra, V; Lanzillo, R
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression
2023 Scandurra, C.; Rosa, L.; Carotenuto, A.; Moccia, M.; Arena, S.; Ianniello, A.; Nozzolillo, A.; Turrini, M.; Streito, L. M.; Abbadessa, G.; Ferraro, E.; Mattioli, M.; Chiodi, A.; Maldonato, N. M.; Bonavita, S.; Clerico, M.; Cordioli, C.; Moiola, L.; Patti, F.; Lavorgna, L.; Filippi, M.; Borriello, G.; D’Amico, E.; Pozzilli, C.; Brescia Morra, V.; Petracca, M.; Lanzillo, R.
Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment
2026 Russo, C.; Fusco, C.; Carbone, F.; Micillo, T.; La Rocca, C.; De Rosa, G.; Di Marino, V.; Ruggiero, K.; Garziano, F.; Perna, F.; Zannella, C.; Galdiero, M.; Franci, G.; Lanzillo, R.; Brescia Morra, V.; Bigi, R.; Abbadessa, G.; Bonavita, S.; Salvetti, M.; Moccia, M.; Procaccini, C.; Matarese, G.
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies
2026 Naing, A; Lin, Cc; Patel, Mr; Curigliano, G; Burris, Ha; Thistlethwaite, F; De Braud, F; Minchom, A; Ascierto, Pa; Wake, M; Nguyen, Ma; Abbadessa, G; Sainson, Rca; Palu, Cc; Quaratino, S; Deantonio, C.
Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers
2026 Rojas, C; Mortier, L; Park, Jj; Matamala, L; Baakili, A; Rao, S; Xu, J; Andrieu, L; Wang, R; Wang, H; Paehler, T; Abbadessa, G; Ascierto Pa., Phase 1/2 Study Of Pegenzileukin; a pegylated recombinant non-alpha, IL-2; With Cemiplimab For The Treatment Of Advanced Unresectable Or Metastatic Skin, Cancers.
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors | 1.1 Articolo in rivista | 2023 | Petracca, M; Carotenuto, A; Scandurra, C; Moccia, M; Rosa, L; Arena, S; Ianniello, A; Nozzolillo, A; Turrini, M; Streito, L M; Abbadessa, G; Cellerino, M; Bucello, S; Ferraro, E; Mattioli, M; Chiodi, A; Inglese, M; Bonavita, S; Clerico, M; Cordioli, C; Moiola, L; Patti, F; Lavorgna, L; Filippi, M; Borriello, G; D'Amico, E; Pozzilli, C; Brescia Morra, V; Lanzillo, R | |
| Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression | 1.1 Articolo in rivista | 2023 | Scandurra, C.; Rosa, L.; Carotenuto, A.; Moccia, M.; Arena, S.; Ianniello, A.; Nozzolillo, A.; Turrini, M.; Streito, L. M.; Abbadessa, G.; Ferraro, E.; Mattioli, M.; Chiodi, A.; Maldonato, N. M.; Bonavita, S.; Clerico, M.; Cordioli, C.; Moiola, L.; Patti, F.; Lavorgna, L.; Filippi, M.; Borriello, G.; D’Amico, E.; Pozzilli, C.; Brescia Morra, V.; Petracca, M.; Lanzillo, R. | |
| Effect of dynamics and timing of SARS-CoV-2 vaccination on immune response in people with multiple sclerosis during cladribine treatment | 1.1 Articolo in rivista | 2026 | Russo, C.; Fusco, C.; Carbone, F.; Micillo, T.; La Rocca, C.; De Rosa, G.; Di Marino, V.; Ruggiero, K.; Garziano, F.; Perna, F.; Zannella, C.; Galdiero, M.; Franci, G.; Lanzillo, R.; Brescia Morra, V.; Bigi, R.; Abbadessa, G.; Bonavita, S.; Salvetti, M.; Moccia, M.; Procaccini, C.; Matarese, G. | |
| First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies | 1.1 Articolo in rivista | 2026 | Naing, A; Lin, Cc; Patel, Mr; Curigliano, G; Burris, Ha; Thistlethwaite, F; De Braud, F; Minchom, A; Ascierto, Pa; Wake, M; Nguyen, Ma; Abbadessa, G; Sainson, Rca; Palu, Cc; Quaratino, S; Deantonio, C. | |
| Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers | 1.1 Articolo in rivista | 2026 | Rojas, C; Mortier, L; Park, Jj; Matamala, L; Baakili, A; Rao, S; Xu, J; Andrieu, L; Wang, R; Wang, H; Paehler, T; Abbadessa, G; Ascierto Pa., Phase 1/2 Study Of Pegenzileukin; a pegylated recombinant non-alpha, IL-2; With Cemiplimab For The Treatment Of Advanced Unresectable Or Metastatic Skin, Cancers. |